Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2023

Mularoni V, Donati B, Tameni A, Manicardi V, Reggiani F, Sauta E, et al. Long non-coding RNA mitophagy and ALK-negative anaplastic lymphoma-associated transcript: a novel regulator of mitophagy in T-cell lymphoma. Haematologica. 2023;108(12):3333-3346.

Tylawsky DE, Kiguchi H, Vaynshteyn J, Gerwin J, Shah J, Islam T, et al. P-selectin-targeted nanocarriers induce active crossing of the blood-brain barrier via caveolin-1-dependent transcytosis. Nat Mater. 2023;22(3):391-399.

Chen R, Chen D, Ong S, Lo D, DeSimone RA, Cushing MM, et al. Visualization dashboard for blood product inventory management. Transfusion. 2023;63(5):906-907.

SahBandar IN, Sy CB, van den Akker T, Kim D, Geyer JT, Chadburn A, et al. Primary Effusion Lymphoma in an HIV-Negative Patient with Chronic Myeloid Leukemia Treated with Dasatinib. Pathobiology. 2023;90(5):356-364.

Simner PJ, Bard JD, Doern C, J Johnson K, Westblade L, Yenokyan G, et al. Reporting of Antimicrobial Resistance from Blood Cultures, an Antibacterial Resistance Leadership Group Survey Summary: Resistance Marker Reporting Practices from Positive Blood Cultures. Clin Infect Dis. 2023;76(9):1550-1558.

Galassi C, Klapp V, Formenti SC, Demaria S, Galluzzi L. Immunologically relevant effects of radiation therapy on the tumor microenvironment. Essays Biochem. 2023.

Saoud C, Lam H, Ali SZ. Fine-Needle Aspiration of Sarcomas Metastatic to Lymph Nodes: A Cytomorphologic Study over a 10-Year Period. Acta Cytol. 2023;67(5):493-506.

Helfgott DC, Racine-Brzostek S, Short KJ, Zhao Z, Christos P, Nino I, et al. Immunogenicity of COVID-19 mRNA vaccines in patients with acute myeloid leukemia and myelodysplastic syndrome. Leuk Lymphoma. 2023;64(3):662-670.

Mukhopadhyay C, Zhou P. Role(s) of G3BPs in Human Pathogenesis. J Pharmacol Exp Ther. 2023;387(1):100-110.

Gomez-Arteaga A, Orfali N, Pasciolla M, Baptiste A, Guindine I, Hsu JM, et al. Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (ESKD). Bone Marrow Transplant. 2023;58(7):835-838.